久方生技 7608 股份有限公司

02/06/2025

Taiwan's MedTech Sector Embraces Value Chain Innovation: A Strategic Blueprint for Global Leadership, Domestic Production, and Resilient Supply Chains

TAIPEI, TAIWAN – Jun 02, 2025 – Taiwan's MedTech industry is undergoing a pivotal transformation! Dr. Hsiao-Wei Tang, General Manager of Maxima Biotech Co., Ltd., recently delivered a keynote speech at the "2025 Taiwan International Medical Industry Delegation" hosted by the Overseas Community Affairs Council, dissecting the opportunities and strategic blueprint for MedTech innovation in Taiwan. He highlighted how Value Chain Innovation, rooted in Michael Porter's seminal theories, is driving the localization of high-value medical devices and the construction of robust supply chains.

Dr. Tang defined Value Chain Innovation as a systematic approach to integrating, optimizing, and innovating various internal business activities—from product R&D and manufacturing to supply chain management, marketing, and customer service—to create higher product or service value and enhance overall competitiveness. Drawing from Michael Porter's value chain framework, Dr. Tang explained that this approach allows companies to simultaneously pursue both cost leadership and differentiation. Taiwan, with its strengths in precision manufacturing and a highly efficient supply chain, can achieve cost advantages while differentiating through product and process innovation. He emphasized that in the current global climate, Taiwan's exceptional MedTech capabilities and strong ICT foundation enable a transition from contract manufacturing to a high-value "strategic partner".

Drawing on Maxima Biotech's experience, Dr. Tang illustrated how the company's commitment to "incremental innovation" has been a core success factor. Maxima Biotech strategically targets products with proven technology, strong market potential, and opportunities arising from patent cliff. This approach is guided by an agile "innovation optimization loop" (often seen as MVP → PMF → Pivot in startups), ensuring continuous alignment with clinical needs and maintaining a competitive edge. Maxima Biotech's competitive advantage lies in delivering product performance equivalent to leading global manufacturers, but at a more competitive cost, leveraging Taiwan's strengths in advanced manufacturing and cost-efficiency.

This practical application of Value Chain Innovation has yielded significant results: since its launch in 2022, Maxima Biotech's cordless ultrasonic dissector has been used in over 3,500 surgical cases in Taiwan and has successfully gained adoption in 80 hospitals, capturing over 10% of the market share.

Dr. Tang stated that Taiwan's MedTech industry already possesses innovative technology and manufacturing prowess, having validated a successful model of Value Chain Innovation. Looking ahead, Maxima Biotech will continue to deepen its presence in the Taiwanese market, translating accumulated clinical data into international promotion materials. Through diverse strategies such as "Niche Market Leadership," "Strategic Partnership", or "Turnkey Solutions," the company aims to accelerate international market expansion, maintaining technological leadership and competitive advantages.

"The global Taiwanese diaspora plays an irreplaceable and crucial role in the worldwide MedTech value chain," Dr. Hsiao-Wei Tang emphasized, highlighting their potential as partners for market expansion, connecting capital and technology, and building resilient supply chains globally.

30/04/2025

久方生技攜手伍斯特理工學院，產學合作深耕國際市場

[台灣台中] – [2025年4月28日] – 久方生技股份有限公司與美國伍斯特理工學院 (WPI) 展開策略合作，由 WPI 學生團隊在久方生技的指導下，針對其產品進行深入的專利風險評估，並協助制定全面的國際市場進入策略，以期在全球市場取得更強勁的競爭優勢。特別感謝國家科學及技術委員會促成WPI與台灣的專題合作，並於台灣設立課題研究中心，為本次合作奠定重要基礎。

成立於 1865 年的伍斯特理工學院Worcester Polytechnic Institute (WPI)是一所美國頂尖的私立研究型大學，以其在工程和科技領域的卓越表現聞名。WPI 提供超過 70 個科學、工程、技術、商業與管理、以及人文藝術等領域的學士、碩士和博士學位課程。WPI 強調專案導向學習，鼓勵學生透過實際專案和團隊合作來應用理論知識，培養批判性思維和實踐能力。WPI 在美國大學排名中名列前茅，例如在 US News & World Report 中位列前 80 名。WPI 在全球 31 個國家設有 50 多個課題研究中心。

此次 WPI 合作團隊由 Prof. Burrier 及 Prof. Hultquist 領軍，包含五位來自不同領域的三年級學生，展現 WPI 強調跨領域合作的精神。在久方生技的指導下，WPI 團隊將以實作方式學習，深入了解醫療器材產業的市場特性與專利布局策略。

久方生技說明其在進入國際市場的實務，引導 WPI 團隊進行包含市場評估、客戶策略與客戶心聲分析、競爭分析、客戶購買流程理解等深入的市場研究。同時，久方生技也指導WPI團隊針對現有專利，考量地區及市場、申請時間、技術深度及廣度等多個變項，進行專利監控及迴避設計，並參考Ove Granstrand教授提出的專利布局策略，擬定攻擊性專利策略與防禦性專利策略，並思考專利授權及技術商品化等多種專利運用方式。

透過久方生技的實務指導與 WPI 團隊的學術能量結合，此合作案不僅為久方生技帶來新的市場洞察與專利策略，更讓 WPI 學生團隊獲得寶貴的實作經驗。久方生技期望能透過這次產學合作，有效降低市場進入風險，並最大化市場拓展效益。

WPI 團隊已抵台展開為期七週的實地研究，初期會議已針對地理專利現狀分析及市場進入策略進行深入探討，並著手開發專利監控應用程式 (App) 以強化智財管理。團隊也於 4 月 24 日參訪久方中科研發中心，親身體驗其高階能量電刀的卓越性能。

久方生技致力於高階能量醫療器械的創新與製造，其國產無線超音波刀已通過 TFDA 認證，並在台灣累積逾 3500 例成功臨床案例。公司以普及微創手術為己任，期許提供更易於負擔且高品質的醫療方案。透過與 WPI 等國際學術機構的合作，久方生技不斷提升自身實力，為進軍全球市場奠定堅實基礎。WPI 團隊的最終研究成果將於 5 月 2 日在東吳大學公開發表。

25/04/2025

久方生技整合台灣優勢共創可用、可及、可負擔微創手術未來
Make Minimally Invasive Surgery Available, Accessible, and Affordable

台灣，台北 2025年4月25日 訊 – 在全球人口老化、醫療成本攀升及供應鏈重組的多重挑戰下，實現讓微創手術普及化Available、易於獲取Accessible、且價格可負擔Affordable的目標，已成為全球醫療創新的核心焦點。值此關鍵時刻，久方生技在Ircad Taiwan 秀傳亞洲遠距微創手術中心的多次安排下，與全球微創手術先驅 Prof. Jacques Marescaux交流，闡述公司如何承襲IRCAD的變革精神與臨床創新網絡，展示台灣已臻成熟的微創手術產業生態系，致力於將高品質微創手術醫材推向全球，加速臨床創新優化，並提出協助夥伴國家建立在地醫療韌性的前瞻模式。

IRCAD：加速外科典範轉移的革命性力量
傳統外科教育以一對一師徒制，難以應對微創手術等新技術的快速普及需求。由Prof. Jacques Marescaux創立的IRCAD網絡，以其系統化、規模化的教育平台及WebSurg等數位工具，將專家知識核心，高效輻射至全球學習者，徹底改變外科學習曲線，極大加速了微創手術的全球化進程。久方生技總經理湯孝威博士表示：「Marescaux教授對全球外科教育及MIS普及的貢獻是革命性的，其對全球人類的影響力堪稱諾貝爾獎級別。」

全球變局下的挑戰與台灣契機
全球醫材市場雖由老齡化及智慧醫療需求驅動成長，但也面臨嚴峻的醫療成本壓力與地緣政治風險。國際大廠在啟動美國製造的同時，也積極尋求具備可靠性與高品質的供應鏈夥伴，為技術領先的台灣CDMO廠商帶來新的策略合作契機。然而，關稅壁壘與供應鏈不確定性，也迫使台灣產業必須憑藉持續的技術創新與極致的營運效率，積極開拓包括美國在內的全球多元市場。

久方生技：整合創新，提供高性價比解決方案
在此變局中，久方生技精準定位於提供國際大廠質量，更具成本競爭力的醫材。公司自創立初期即獲『非佳不可』Qisda 佳世達科技 醫療大艦隊的全力支持，運用台灣在資通訊 ICT 與精密製造的深厚實力，專注於高技術門檻的微創手術能量器械。
「我們的核心策略是建立一個從臨床需求洞察到高效製造的『創新迴圈』。」湯博士解釋道。「透過與臨床醫師的緊密連結，我們將第一線回饋迅速導入研發與生產，實現敏捷開發與持續優化。」目前，久方生技的無線超音波刀已獲TFDA核准，在台灣逾80家醫院累積超過3500例手術實績，充分驗證了產品的臨床信賴度與市場潛力，並運用「乙組冠軍策略」進軍國際市場。

策略夥伴關係：實踐「小幫手策略」與共創價值
為加速創新落地與拓展全球市場，久方生技積極尋求與國際領導企業建立互補的策略夥伴關係，這即是公司的「小幫手策略」核心。與IRCAD Taiwan的緊密合作便是此策略的關鍵實踐：這不僅加速了久方對於前沿臨床需求的洞察與創新醫材的實現，更能運用IRCAD無可比擬的全球網絡與教育平台，對創新概念與產品進行快速驗證和優化。透過此合作模式所產生的關鍵智慧財產權 IP 與臨床數據 Data，將為久方生技尋求與國際大廠進行更深層次的技術合作或市場授權，奠定極為重要的基礎。

「整廠輸出」：賦能夥伴，共建在地醫療韌性
面對世界各國將醫療供應鏈視為國家安全戰略的高度重視，久方生技正將其在台灣驗證成功的整合模式，發展為可複製、可輸出的解決方案。「我們正積極探索『整廠輸出』Turnkey Solution 的合作模式，」湯博士表示，「在全球化面臨挑戰、貿易壁壘升高的時代，協助有意願的國家建立自主、高品質且具成本效益的必要醫材供應鏈，不僅是對地緣政治風險的回應，更是強化全球健康體系韌性、實現醫療在地化的具體路徑。」

展望未來：從代工走向策略夥伴
在全球結構重組趨勢下，台灣醫材產業需從傳統代工模式，轉型為具備高附加價值的策略夥伴。久方生技將持續強化高值創新、深化臨床鏈結、打造智慧韌性供應鏈。

湯博士總結：「結合IRCAD的全球影響力與台灣的產業優勢，久方生技致力於提供高品質、可負擔的微創手術解決方案，我們採取的『乙組冠軍策略』，目標是成為國際品牌之外，最具領導性的高價值選項；同時，我們也透過實踐『小幫手策略』，與IRCAD Taiwan的深度合作，積極尋求與國際大廠互補的策略性合作機會。最終，我們更期望透過『整廠輸出』模式賦能全球夥伴，共同為實現微創手術普及化Available、易於獲取Accessible、且價格可負擔Affordable的目標貢獻力量，提升全人類的健康福祉。」

22/04/2025

FOR IMMEDIATE RELEASE

Maxima Biotech Completes PwC Taiwan Accelerator, Unveils Growth Strategy and Market Impact at Demo Day

TAIPEI, Taiwan – April 23, 2025 – Maxima Biotech Inc., a leading innovator in advanced surgical energy devices, today announced the successful completion of the PwC Taiwan Entrepreneur Growth Accelerator Scale Programme. Over the past six months, Maxima Biotech received tailored strategic guidance and comprehensive support from PwC, accelerating the company’s transformation and market expansion.

This partnership enabled Maxima Biotech to sharpen its growth strategy, optimize operations, and deepen engagement with industry partners and capital markets.

At today’s Demo Day, Dr. Tom Tang, PhD, CEO of Maxima Biotech, presented the company’s strategic vision. He highlighted how Maxima Biotech leverages Taiwan’s technological strengths and clinical expertise to carve out a unique position in the global medical device market. The company’s focus is on advanced surgical energy devices, delivering world-class technology with Taiwan’s renowned cost efficiency and innovative agility.

“We are committed to empowering clinicians with advanced surgical tools—akin to the legendary ‘Heavenly Sword’ and ‘Dragon Slaying Saber’—renowned for their unmatched performance,” said Dr. Tang. “By closely integrating with Taiwan’s robust supply chain and incorporating real-world surgeon feedback, we accelerate product innovation and maintain a sharp competitive edge.”

Since launching its flagship Cordless Ultrasonic Dissector in 2022, Maxima Biotech’s devices have been rapidly adopted in 80 hospitals across Taiwan, supporting over 3,500 surgical cases. Building on this momentum, the company is set to introduce the world’s second Curved Jaw Cordless Ultrasonic Dissector, further expanding its portfolio of advanced surgical solutions.

Maxima Biotech’s mission is to translate Taiwan’s technological and medical strengths into high-value medical devices that benefit patients worldwide. By harnessing local innovation and operating as a strategic hub for cost-effective production and Asian distribution, the company aims to address significant unmet clinical needs on a global scale.

Reflecting on the accelerator experience, Dr. Tang remarked, “The PwC Taiwan Scale Programme has been instrumental for Maxima Biotech. The exceptional support and resources provided critical guidance and strengthened our industry connections at a pivotal stage. We are grateful for PwC’s partnership and excited for the next phase of innovation and global expansion.”

About Maxima Biotech Inc.
Maxima Biotech Inc. is a Taiwanese leader in advanced surgical energy devices, recognized for rapid product development, strong clinical adoption, and scalable, cost-effective manufacturing. The company’s portfolio features the world’s second cordless ultrasonic dissector and a pipeline of minimally invasive solutions. Maxima Biotech delivers agile R&D, OEM/ODM collaboration, and robust supply chain integration from its strategic Asia hub.

13/02/2025

MAXIMA Biotech Joins Flinders University's Work Integrated Learning Program

MAXIMA Biotech (7608) is thrilled to announce its successful collaboration with Flinders University's Work Integrated Learning (WIL) program. Over an enriching 20-week internship, we had the privilege of hosting two exceptional students, Jonas and Joanne, whose enthusiasm and dedication brought immense value to our organization.
During their internship, Jonas and Joanne gained practical insights into the medical device industry through a variety of activities, including:
-Observing Advanced R&D Processes: The students immersed themselves in the complete research and development cycle of cutting-edge medical devices at MAXIMA Biotech.
-Regulatory and Clinical Data Analysis: They actively participated in collecting and analyzing regulatory and clinical data, deepening their understanding of compliance and evidence-based practices.
-Studying Biodesign Principles: Through an in-depth exploration of Biodesign: The Process of Innovating Medical Technologies, they learned how to conceptualize and develop medical innovations. Additionally, they contributed to the creation of three specialized lectures on medical device innovation.

This collaboration offered Jonas and Joanne invaluable hands-on experience in Taiwan's rapidly growing medical device sector. At the same time, partnering with Flinders University strengthened MAXIMA Biotech's innovation processes and enhanced its international visibility.

We firmly believe that academic-industry partnerships like this are essential for fostering cross-disciplinary talent capable of driving innovation in the global medical device industry.
MAXIMA Biotech looks forward to continuing these meaningful collaborations to nurture talent and contribute to the growth of the medical device sector worldwide. We extend our heartfelt gratitude to Jonas, Joanne, and Flinders University for making this partnership a remarkable success.

24/01/2025

09/01/2025

Maxima Biotech Inc., established in April 2019, has rapidly emerged as a dynamic and innovative force in the medical device industry. Specializing in the rapid commercialization of minimally invasive surgical (MIS) products, the company positions itself as a strategic partner for global medtech leaders and innovators by delivering a unique combination of cutting-edge innovation and cost-effective manufacturing solutions.

Headquartered in the technological hub of Taiwan, Maxima Biotech harnesses Taiwan's world-renowned electronic and precision manufacturing capabilities and engineering talents. This strategic location provides us with a significant competitive edge in the global medical device market, enabling us to leverage Taiwan's formidable strengths in innovation, high-tech manufacturing, and streamlined supply chain management.

Our commitment to groundbreaking innovation is powerfully demonstrated by our recent achievement: the development of the world's second cordless ultrasonic dissector. This state-of-the-art device, brought to market in an unprecedented three-year timeframe, exemplifies our ability to swiftly create and commercialize advanced surgical tools that set new industry standards. This accelerated development cycle showcases both our technical prowess and our agility in responding to market needs while expediting the journey from concept to commercialization.

By combining Taiwan's manufacturing excellence with our innovative approach to product development, Maxima Biotech is uniquely positioned to deliver high-quality, cost-effective MIS solutions that meet the evolving demands of the global healthcare industry. Our proven track record in bringing cutting-edge devices to market efficiently underscores our value as an essential partner for healthcare leaders seeking to stay at the forefront of medical technology.

06/01/2025

We are immensely thankful to our Maxima Biotech team, investors, partners, and suppliers for making 2024 a truly remarkable year! Together, we established the Maxima R&D Center, achieved ISO 13485 certification, and successfully launched our cordless surgical scalpel to the market. Your trust and collaboration drive us to innovate and deliver cutting-edge medical devices.

Looking ahead, our "Minor League Strategy" focuses on delivering high-performance, cost-effective solutions to underserved markets by addressing unmet needs with precision and efficiency. Meanwhile, our "Little Helper Strategy" empowers global medtech leaders with rapid product development, streamlined certifications, market validation, and scalable production for next-generation innovations.

With Taiwan’s strengths in innovation and precision manufacturing as our foundation, Maxima Biotech is committed to being your trusted partner in shaping the future of global healthcare. Let’s continue building a healthier tomorrow together!

28/11/2024

# 久方生技展現台灣醫材整合實力 引領產業創新轉型

**結合科技業供應鏈優勢及醫材品質系統 獲國際醫療KOL肯定**

台灣台中 - 2024年11月28日

久方生技股份有限公司今日發布最新營運進展，展現其以系統整合能力為核心的創新商業模式。公司整合創新策略不僅獲得美國知名創投肯定，更進軍國際醫材領導廠商進行產品效能評估，加上全球頂尖微創手術中心權威專家的肯定，多重國際認可驗證台灣醫材產業在全球供應鏈重組中的關鍵角色。

「台灣的競爭優勢不僅在於高科技及製造，更在於整合。」久方生技董事長洪一平表示，「我們成功整合台灣ICT產業的敏捷開發、傳產的精密製造，以及醫療產業的臨床經驗，打造出世界級醫材研發及量產能力。這種整合能力不僅讓我們通過全球領導廠商的嚴格測試，更在全球醫材供應鏈重組的浪潮中，展現出獨特的競爭優勢。」

久方生技總經理湯孝威博士詳述公司的創新研發方法論：「我們建立了一套符合國際醫材品質系統設計管制(Design Control)要求的產品開發流程，並將台灣科技業成熟的模組化開發及供應鏈管理方法融入其中。這種創新的整合讓我們在嚴謹的品質要求下，仍保有科技業快速迭代的優勢。」藉由這套獨特的開發模式，久方不僅確保產品品質符合全球市場的醫材法規要求，更大幅提升研發效率，使2024年前三季營收已達2023年全年水準。

在通路布局方面，久方生技展現精準的策略眼光。公司掌握康德生醫六成股份，建立起從研發、生產到銷售的完整產業生態系。這種垂直整合模式使公司能快速收集市場反饋，並在符合品質系統要求的前提下，以最短時間完成產品優化，充分發揮台灣供應鏈的速度優勢。產品已成功打入全台14家醫學中心，總計56家醫療院所，驗證其解決方案的實用性與可靠性。

在國科會支持下，久方生技連續兩年參與全球最大醫材展MEDICA，不僅向國際展現台灣醫材供應鏈的實力，更持續深化與全球醫材大廠的合作討論。「這些國際夥伴關係證明台灣醫材產業已經具備在高階醫材市場與國際大廠策略合作的實力，」洪一平強調。

在基礎建設方面，位於中科的研發中心已完工並取得使用執照，預計2025年底完成醫療器材製造業者品質管理系統(QMS)認證。第二代產品已突破關鍵技術瓶頸，預計2025年第三季完成臨床前測試，新產品線也持續擴充中。全球頂尖微創手術中心創辦人親自蒞臨久方中科研發中心指導。該專家高度讚揚公司在研發速度、量產效率及成本優勢上的表現，認可台灣在高階醫材領域的發展潛力。

「台灣醫材產業正處於關鍵轉型期，」湯孝威表示，「我們期待以創新的整合模式為產業注入新動能，展現台灣科技供應鏈跨足高階醫材的成功範例。」久方生技以2027年IPO為目標，致力於為台灣醫材產業開創新局，不僅展現台灣在全球醫材供應鏈中的戰略價值，更為其他台灣科技業者跨入醫材領域提供了寶貴經驗。

# # # 關於久方生技
久方生技股份有限公司運用台灣精密製造優勢，專注開發新世代無線微創手術器械。公司以創新的系統整合方法論為核心，結合國際醫材品質系統規範與台灣科技業優勢，建立模組化技術平台，打造從研發、製造到銷售的完整產業生態系。作為台灣醫材產業升級的先行者，久方生技正以獨特的商業模式，開創高階醫材的新藍海。

# # # 媒體聯絡
久方生技股份有限公司
電話：(+886)04-2358-5556

23/11/2024

Fast Track Medical Innovation to Market

The adoption of new technology in medtech is notoriously slow, expensive, and fraught with challenges—only 1 in 3,000 innovations reach the market. Leveraging Taiwan's advanced technologies and exceptional adaptability, we can overcome these barriers.

At Maxima Biotech, we excel in accelerating product commercialization through cost-effective manufacturing and seamless collaboration with clinical experts and innovators.

Today, at Meet Taipei—Taiwan's premier innovation event—we highlight our capability to merge Taiwan's deep technical expertise with a keen understanding of market needs. An exemplary case is our cordless surgical scalpel, which reached the market in just three years, and its upgraded second generation is already poised for release. This showcases our commitment to continuous innovation and market readiness.

Maxima Biotech, Your Global CDMO Partner for Surgical Innovation